Cancer Vaccines Market Seen Growing 36% Through 2036 as US Holds 87% Share
Updated
Updated · PR Newswire · Sep 21
Cancer Vaccines Market Seen Growing 36% Through 2036 as US Holds 87% Share
1 articles · Updated · PR Newswire · Sep 21
Summary
DelveInsight projects the cancer therapeutic vaccines market to expand 36% from 2026 to 2036, after reaching about $335 million across the US, EU4, UK and Japan in 2025.
Rising cancer incidence, broader treatment access and newer platforms—especially personalized and mRNA vaccines—are expected to drive demand across melanoma, NSCLC, bladder, prostate, breast and pancreatic cancers.
The US accounted for 87% of the seven-market total in 2025, while prostate cancer had the largest target population at roughly 2.8 million cases and is expected to represent about 18% of the market by 2036.
Pipeline momentum is centered on candidates including OSE-2101, Merck and Moderna's intismeran autogene, IO Biotech's IO102-IO103, Sellas' galinpepimut-S and BioNTech's BNT113, with combination use alongside PD-1/PD-L1 drugs increasingly shaping development.
The report says the field is moving from experimental immunotherapy toward a broader commercial opportunity, though developers still face a key hurdle in turning immune responses into consistent late-stage clinical benefits.